Stockscreener 앱 받기
1.19
0.00%
0.00
시간 외 거래:
1.19
전일 마감가:
$1.19
열려 있는:
$1.27
하루 거래량:
8,124
Relative Volume:
0.78
시가총액:
$15.09M
수익:
$3.37M
순이익/손실:
$-57.28M
주가수익비율:
-0.1107
EPS:
-10.7522
순현금흐름:
$-51.83M
1주 성능:
+0.85%
1개월 성능:
-1.75%
6개월 성능:
-20.52%
1년 성능:
-18.06%
1일 변동 폭
$1.19
$1.27
1주일 범위
$1.18
$1.27
52주 변동 폭
$0.898
$1.88
신로직 Stock (SYBX) Company Profile
명칭
Synlogic Inc
전화
617-659-2802
주소
PO BOX 30, WINCHESTER, MA
SYBX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYBX
Synlogic Inc
|
1.19 | 15.09M | 3.37M | -57.28M | -51.83M | -10.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.36 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.75 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.50 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
538.64 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.47 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
신로직 Stock (SYBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-11-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-21 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2019-04-30 | 개시 | Jefferies | Buy |
| 2018-12-13 | 개시 | Chardan Capital Markets | Buy |
| 2018-03-19 | 개시 | H.C. Wainwright | Buy |
| 2018-01-29 | 개시 | Piper Jaffray | Overweight |
모두보기
신로직 주식(SYBX)의 최신 뉴스
Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key - openPR.com
Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com
Synlogic's executive sells shares worth $2,802 - MSN
5 Best Microbiome Companies (June 2025) - Securities.io
Synlogic Inc. Reports Strategic Shift and Positive Earnings - TipRanks
Synlogic (NASDAQ:SYBX) Stock Passes Below Two Hundred Day Moving Average – What’s Next? - Defense World
Synlogic (SNDX) to Attend Meeting Hosted by B. Riley in New York - GuruFocus
Synlogic (SYBX) Projected to Post Earnings on Tuesday - Defense World
Gene Circuits Market on the Rise with Advancements in Synthetic Biology | Synlogic, Synthego, Ginkgo Bioworks - openPR.com
Renaissance Technologies LLC Decreases Stake in Synlogic, Inc. (NASDAQ:SYBX) - Defense World
Synlogic’s executive Mary Beth Dooley sells $172 in common stock - Investing.com Australia
Synlogic’s executive Mary Beth Dooley sells $172 in common stock By Investing.com - Investing.com UK
SYBX stock touches 52-week low at $1.14 amid market challenges - Investing.com India
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - Business Wire
Gallium Arsenide Market Applications and Semiconductor Industry Impact - openPR.com
Synlogic (NASDAQ:SYBX) Shares Pass Below Fifty Day Moving Average – Here’s Why - Defense World
SYBX stock touches 52-week low at $1.15 amid market challenges - Investing.com Australia
Synlogic (SYBX) to Release Quarterly Earnings on Tuesday - Defense World
Synlogic Inc. (SYBX) reports earnings - Quartz
Week Ahead (Nov.2226): FDA Decision, Data Presentations (ABEO, SYBX, AADI…) - RTTNews
CRISPR and Cas Gene Market May Set a New Epic Growth Story | Fate Therapeutics, Cellectis, Synlogic - Newstrail
Microbiomes Market to Grow by USD 824.3 Million (2025-2029) with Rising Disease Prevalence Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve
Synlogic's executive sells shares worth $2,802 By Investing.com - Investing.com South Africa
Promising Growth Expected in Gout Therapeutics Market, Set to Reach $5.03 Billion by 2029 with a CAGR of 11.7% - WhaTech
Synlogic (SYBX) Stock Price, News & Analysis - MarketBeat
Synlogic announces board member resignation By Investing.com - Investing.com Canada
Synlogic announces board member resignation - Investing.com
The definitive Boston biotech layoff tracker for 2024 - The Business Journals
Biopolymers Market to Reach USD 47.4 Billion by 2032 Driven - GlobeNewswire
Only the paranoid survive, and the CEO’s paradox, from Aoife Brennan - BioCentury
Urea Cycle Disorder Treatment Market to Grow by USD 215.4 Million (2024-2028), Driven by Rising Prevalence, with AI Redefining Market LandscapeTechnavio - PR Newswire
Phenylketonuria Market size is ~700 USD million in 2023, asserts DelveInsight | Pharma Giants: PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals - The Globe and Mail
Synlogic Third Quarter 2024 Earnings: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023) - Yahoo Finance
Synlogic Reports Third Quarter 2024 Financial Results - GlobeNewswire
The 2024 Biotech Graveyard - Fierce Biotech
(PDF) The effects of caffeinated and decaffeinated coffee on sex hormone-binding globulin and endogenous sex hormone levels: A randomized controlled trial - ResearchGate
Oxygen Scavenger Market Set to Reach USD 8.2 Billion by - GlobeNewswire
Synlogic Reports Second Quarter 2024 Financial Results - GlobeNewswire
Xilio Therapeutics Appoints Aoife Brennan and James Shannon to its Board of Directors - citybiz
Gut Microbiota Market Set to Reach a Staggering US$ 3,600.1 Million by 2032 - BioSpace
Synlogic Reports First Quarter 2024 Financial Results - GlobeNewswire
Designer Genes: Synlogic Is Crafting Living Therapeutics Programmed to Treat Disease: - Mary Ann Liebert, Inc.
Human Microbiome Market Size & Share to Surpass USD 2,555 million by 2030 - WhaTech
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire
Synlogic Adopts Limited Duration Stockholders Rights Plan - GlobeNewswire
Irish-led Synlogic to cease operations after ending drug trial - Silicon Republic
Synlogic Announces Plan to Cease Operations and Reduce Its Workforce by More Than 90% - SynBioBeta
Synlogic shuts down after PKU drug fails phase 3 trial - pharmaphorum
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update - Yahoo Finance
Synlogic Announces Publication of Preclinical and Clinical - GlobeNewswire
Sidoti Events, LLC's Virtual January Micro-Cap Conference - FinancialContent
신로직 (SYBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
신로직 주식 (SYBX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dooley Mary Beth | See Remarks below |
Feb 03 '25 |
Sale |
1.33 |
2,107 |
2,802 |
13,045 |
| Dooley Mary Beth | Head of Finance |
Oct 29 '24 |
Sale |
1.40 |
79 |
111 |
15,152 |
3.56%
0.22%
자본화:
|
볼륨(24시간):